Natural Killer Cell Lymphomas Market to Reflect Impressive Growth Rate by 2019

Lymphoma is a common blood cancer type which develops when lymphocytes multiply in an uncontrolled manner. There are two types of lymphomas- Hodgkin’s and non-Hodgkin’s lymphoma, out of which non-Hodgkin’s lymphoma is more common. Natural killer cell (NK) lymphoma is a type of non-Hodgkin’s lymphoma. There are three types of NK cell lymphomas namely, extranodal, nasal type and aggressive NK cell lymphoma. Extranodal lymphomas occur in organs other than lymph nodes, hence called as extranodal lymphomas. Nasal type of NK cell lymphomas usually affects nasal areas and paranasal sinuses. Aggressive form of the lymphoma is a very fast growing cancer, because of which prognosis is difficult to study. NK cell lymphomas are also shown to be associated with Epstein Barr Virus (EBV).

Read Report Overview: https://www.transparencymarketresearch.com/natural-killer-cell-lymphomas.html

Research and development activities has been impairedbecause of unpredictable prognosis and rare prevalence. Currently Cytoxan (cyclophosphamide), Procytox (cyclophosphamide), Adriamycin(doxorubicin), Oncovin(vincristine), Deltasone (prednisone) are widely used in chemotherapy. While radiation therapy is also practiced for treating the cancer. Various research institutes and corporates are also trying to discover new means to treat the cancer. These include Kirin Holdings Company, Mundipharma International Limited, Fred Hutchinson Cancer Research Center, Sun Yat-sen University, Seoul National University Hospital, University of Minnesota, Zhengzhou University, and M.D. Anderson Cancer Center. Study conducted by Zhengzhou University is currently under Phase IV trial which focuses in evaluation of gemcitabine, pegaspargase, cisplatin, and dexamethasone for chemotherapy.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2361

A study published in Journal of Rare Diseases in 2013, have shown that NK cell lymphomas are common in Asia, Latin America and Central America as compared to North America and Europe. As the prevalence is higher in developing economies, cost of the treatment will be a major barrier for market growth. But a strong pipeline and rising incidences of cancer is expected to support the market in the future.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.